PDF
File
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Vård & Omsorg |
Copenhagen, Denmark, June 27, 2023 - Brain+ A/S (Nasdaq First North: BRAINP)
Brain+ A/S ("BRAINP") today informed that the company has been invited to participate at the 5[th ]Annual DTx Europe conference to be held in London on June 28[-]29[th]. At the conference, CEO Kim Baden-Kristensen will present a Brain+ case study on `Managing the Need for Evidence in a DTx Start-up', scheduled for June 28[th] at 2:10 p.m. BST (3:10 p.m. CET) and speak on a Keynote Panel Discussion on the topic of 'Is the Clinic Ready for DTx?', on June 29[th] at 9:00 a.m. BST (10:00 a.m. CET).
The DTx Europe annual conferences are among the most important conference series for evidence-based digital therapeutics in the US and Europe. Experts from a broad range of stakeholders in the digital therapeutics space are participating, including leading DTx companies, pharma companies, healthcare payers and providers, governmental institutions, academia, policy makers and more. The number of attendees usually counts several hundred. For more information, see DTx Europe: London 2023 (https://www.dtxeurope-london.com/).
The Brain+ case study to be presented will focus on the company's approach to the development of DTx products for dementia and on how to build clinical evidence for digitally delivered Cognitive Stimulation Therapy (CST). CST is the world leading non-pharmacological treatment of dementia, which today is offered as an analog therapist-led and activity-based group therapy. Brain+ is pioneering the digitalization of CST with global experts, including the inventor of CST, and a first version of the company's first digital CST-based product was introduced in Denmark in November 2022.
CST was recommended for global implementation in the World Alzheimer's Report 2022 due to its strong evidence base, but barriers to adoption remain including lack of health care resources and low treatment scalability. Digital delivery of CST can help overcome these barriers, and Brain+ focuses its research and clinical development activities on showing how CST can be scaled cost-effectively via digital delivery, while providing similar or better outcomes for people with dementia. Establishing such evidence can unlock large scale reimbursement and the adoption of digital CST products into large healthcare systems, such as for example the NHS in the UK.
For further information, please contact:
Kim Baden-Kristensen, MSc.
CEO and Co-founder:
Phone: + 45 31393317 (text message)
Mail: kim@brain-plus.com
About Brain+ A/S
Brain+ A/S (publ) (Nasdaq Copenhagen: BRAINP) commercializes digital therapeutics for and conducts research and development in dementia and Alzheimer's disease. The mission of Brain+ is to make effective treatments for cognitive decline in Alzheimer's accessible to everyone as digital therapeutics. For more information, please visit the company's web page: www.brain-plus.com.